Africa IVD Market to be Worth $1.49 Billion by 2030—Exclusive Report by Meticulous Research®

Africa IVD Market by Product & Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User - Forecast to 2030

Redding, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, Africa In Vitro Diagnostics Market by Product & Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User — Forecast to 2030,’ published by Meticulous Research®, the Africa in vitro diagnostics market is expected to reach $1.49 billion by 2030, at a CAGR of 2.8% from 2023 to 2030.

In vitro diagnostics (IVD) are tests performed on samples of blood or tissue taken from the human body to detect a wide range of diseases. These tests help monitor overall health to prevent and treat various diseases. IVD involves the use of various reagents, assays, and kits based on technologies such as immunoassay, whole blood glucose monitoring, molecular diagnostics, point of care, clinical chemistry, hematology, coagulation & hemostasis, critical care, and urinalysis.

Download Free Report Sample Now:

High Prevalence of Infectious Diseases Driving the Growth of the Africa IVD Market

Diagnostic tests are crucial in the medical care of patients with infections. The demand for IVD kits used to diagnose infectious diseases is high in Africa due to the increasing awareness regarding emerging and re-emerging infectious diseases and the adoption of advanced molecular testing and lab-on-chip technology. The burden of diseases such as HIV, tuberculosis, malaria, viral hepatitis, and neglected tropical diseases (NTDs) is large in Africa. For example, according to WHO, in 2020, 25.6 million people were living with HIV in the African Region. The annual number of new HIV infections increased in the Middle East and North Africa (source: UNAIDS data 2021).

In addition, there is a frequent outbreak of endemic diseases in Africa. For instance, Lassa fever is endemic in Nigeria and continues to be reported nationwide, according to Nigeria Centre for Disease Control and Prevention (NCDC). In January 2022, 981 suspected and 211 confirmed cases of Lassa fever were reported in Nigeria. There were 40 deaths reported among confirmed cases, indicating a case fatality rate of 19%. Thus, the high burden of infectious diseases increases the demand for IVD tests in Africa.

Africa IVD Market Outlook

The Africa IVD market is segmented based on Product Category (Reagents, & Kits, Instruments, and Software & Services), Technology (Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassay/Immunochemistry, Biochemistry/Clinical Chemistry, Whole Blood Glucose Monitoring, Hematology, Microbiology, Coagulation & Hemostasis, and Other IVD Technologies), Application (Infectious Diseases, Oncology, Diabetes, Cardiology, Nephrology, Autoimmune Disorders, and Other Applications), Diagnostic Approach (Lab Testing, Point-of-care Testing, and OTC/Self-testing), and End User (Hospitals & Clinics, Diagnostic Laboratories, Home Healthcare, and Other End Users), and Geography (South Africa, Egypt, Nigeria, Kenya,  Algeria, Tanzania, Morocco, Tunisia, and the rest of Africa). The study also evaluates industry competitors and analyzes their market shares.

Have Any Query? Ask To Analyst:

Based on product category, the reagents & kits segment is slated to register the fastest growth rate during the forecast period. In Africa, infectious diseases cause chronic illnesses, premature deaths, and loss of productivity, affecting the region's economic growth. Thus, the emerging threats of infectious diseases drive the demand for IVD in Africa. The frequent use of reagents for diagnosing diseases and the easy availability & accessibility of these tests are the major factors driving the growth of this segment.

Based on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market. Molecular diagnostics is one of the region's most preferred diagnostic testing methods. It focuses on genomic and proteomic analysis to identify disease biomarkers and design better diagnostic assays. The large share of this segment is attributed to the increased prevalence of infectious diseases and the advantages of molecular diagnostics to detect a wide range of pathogens.

Based on application, the cardiology segment is slated to register the fastest growth rate during the forecast period. Africa is home to more than a billion people and is a major contributor to the global burden of cardiovascular disease. According to the World Heart Federation, more than 1 million deaths were estimated to be CVD in sub-Saharan Africa in 2019, which is 5.4% of all global CVD-related deaths and 13% of all deaths in Africa. The large share of this segment is attributed to the high prevalence of cardiovascular diseases, technological advancements in point-of-care testing, and growing awareness for timely diagnosis and monitoring of CVD.

Quick Buy – Africa IVD Market - Opportunity Analysis and Industry Forecast (2023-2030), Research Report:

Based on diagnostic approach, the point-of-care testing segment is slated to register the fastest growth rate during the forecast period. The large share of this segment is attributed to its affordability, easy-to-use nature in limited resources, and faster turnaround time.

Based on end user, the hospitals & clinics segment is slated to register the fastest growth rate during the forecast period. The large share of this segment is attributed to the increased healthcare expenditure, high prevalence of various infectious diseases, and high patient population.

This research report analyzes the market across major African countries and provides a comprehensive analysis of South Africa, Algeria, Nigeria, Kenya, Morocco, Tunisia, Tanzania, Egypt, and the rest of Africa.

Key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

To gain more insights into the market with a detailed table of content and figures, click here:

Scope of the Report

Africa IVD Market Assessment–by Product Category

  • Reagents & Kits
  • Instruments
  • Software & Services

Africa IVD Market Assessment–by Technology

  • Molecular Diagnostics
  • Point-of-care Diagnostics
  • Immunoassay/Immunochemistry
  • Biochemistry/Clinical Chemistry
  • Whole Blood Glucose Monitoring
  • Hematology
  • Microbiology
  • Coagulation & Hemostasis
  • Other IVD Technologies

Note: Other technologies include urinalysis, hybridization, and loop-mediated amplification.

Africa IVD Market Assessment–by Application

  • Infectious Diseases
  • Oncology
  • Diabetes
  • Cardiology
  • Nephrology
  • Autoimmune Disorders
  • Other Applications

Note: Other applications include toxicology, gastroenterology, neonatal, genetic, and neurological disorders.

Africa IVD Market Assessment–by Diagnostic Approach

  • Lab Testing
  • Point-of-care Testing
  • OTC/Self-testing

Africa IVD Market Assessment–by End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home Care
  • Other End Users

Note: Other end users include long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories.

Africa IVD Market Assessment–by Country

  • South Africa
  • Egypt
  • Algeria
  • Nigeria
  • Morocco
  • Kenya
  • Tunisia
  • Tanzania
  • Rest of Africa

Request Free Report Sample Now:

Related Reports:

In-vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030

In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Oligonucleotide, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) - Global Forecast to 2027

IVD Contract Manufacturing Services Market by Type (Assay Development, Manufacturing), Category (Reagents, Systems), Technology (Immunoassay, Molecular Diagnostics, Clinical Chemistry, Hematology, Microbiology, Urinalysis) - Global Forecast to 2028

Indonesia In Vitro Diagnostics Market by Product (Kits, Instruments, Software), Technology (Immunoassay, Hematology, Coagulation, Diabetes, Molecular), Application (Infectious Diseases, Cardiology, Oncology), and End User (Hospital, Diagnostic Lab, Home Care) - Forecast to 2029

Latin America In Vitro Diagnostics Market by Product & Service, Technology (Immunoassay, Point of Care, Molecular Diagnostics), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type — Forecast to 2029

Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli, Tuberculosis, Pneumonia, Cancer)- Forecast to 2029

Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers), Platform (Lateral Flow, Serological, PCR), Application (Blood Glucose, Infectious Diseases, Pregnancy, Drugs of Abuse), End User (Hospitals, Diagnostic Labs, Home Care) - Global Forecast to 2029

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding, 
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Visit Our Website:
Connect with us on LinkedIn-
Content Source:


Contact Data